The α-glucosidase inhibitors effectively compensate for insufficient insulin secretion in insulin-dependent diabetes mellitus by binding to the enzyme and interfering with the dissolution and absorption of monosaccharides (i.e., glucose). Here, INS is linked to diabetes mellitus.